Advertisement
UK markets close in 1 hour 23 minutes
  • FTSE 100

    7,972.88
    +40.90 (+0.52%)
     
  • FTSE 250

    19,889.42
    +78.76 (+0.40%)
     
  • AIM

    743.55
    +1.44 (+0.19%)
     
  • GBP/EUR

    1.1696
    +0.0027 (+0.23%)
     
  • GBP/USD

    1.2631
    -0.0007 (-0.06%)
     
  • Bitcoin GBP

    56,481.41
    +1,140.27 (+2.06%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,252.06
    +3.57 (+0.07%)
     
  • DOW

    39,742.99
    -17.09 (-0.04%)
     
  • CRUDE OIL

    82.61
    +1.26 (+1.55%)
     
  • GOLD FUTURES

    2,234.80
    +22.10 (+1.00%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,504.44
    +27.35 (+0.15%)
     
  • CAC 40

    8,218.13
    +13.32 (+0.16%)
     

Olink to report first quarter 2022 financial results on May 12, 2022

Olink Proteomics AB
Olink Proteomics AB

UPPSALA, Sweden, April 21, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced it will release financial results for the first quarter of 2022 before the market open on Thursday, May 12, 2022. Company management will host a conference call to discuss these results at 8:00 am ET.

Investors interested in listening to the conference call may do so by dialing (833) 562-0120 for domestic callers or (661) 567-1096 for international callers, followed by Conference ID: 5650306. A live webcast of the conference call will be available on the “Investors” section of the Company's website at https://investors.olink.com/investor-relations. The webcast will be archived and available for replay for at least 90 days after the event.

About Olink
Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America, and Asia. Olink is headquartered in Uppsala, Sweden.

ADVERTISEMENT

Investor Contact
Jan Medina, CFA
VP Investor Relations & Capital Markets
Mobile: +1 617 802 4157
jan.medina@olink.com

Media Contact
Andrea Prander
Corporate Communications Manager
Mobile: +46 768 775 275
andrea.prander@olink.com